Companies / Syndax Pharmaceuticals Inc / Activity
Activity — Syndax Pharmaceuticals Inc
28 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Botwood Nicholas A.J. Executive | Sell | Common Stock | $617.0K | -34K -36.02% | 60,885 0.07% of shares | medium |
| Jun 12, 2026 | Botwood Nicholas A.J. Executive | Sell | Common Stock | $566.6K | -31K -33.91% | 60,885 0.07% of shares | medium |
| Jun 12, 2026 | Botwood Nicholas A.J. Executive | Exercise | Common Stock | $431.7K | +31K +51.30% | 92,120 0.10% of shares | low |
| Feb 9, 2026 | Metzger Michael A CEO | Sell | Common Stock | $360.8K | -17K -3.37% | 491,690 0.55% of shares | medium |
| Jun 11, 2026 | Botwood Nicholas A.J. Executive | Exercise | Common Stock | $311.2K | +23K +30.99% | 95,165 0.11% of shares | low |
| Feb 6, 2026 | Metzger Michael A CEO | Sell | Common Stock | $152.8K | -7K -1.44% | 508,849 0.57% of shares | medium |
| Jun 1, 2026 | Metzger Michael A CEO | Sell | Common Stock | $130.0K | -7K -1.39% | 484,843 0.54% of shares | medium |
| Feb 9, 2026 | Goldan Keith A. Executive | Sell | Common Stock | $71.7K | -3K -2.37% | 140,429 0.16% of shares | low |
| Feb 6, 2026 | Goldan Keith A. Executive | Sell | Common Stock | $42.9K | -2K -1.43% | 143,839 0.16% of shares | low |
| Jun 1, 2026 | Goldan Keith A. Executive | Sell | Common Stock | $22.4K | -1K -0.84% | 139,252 0.16% of shares | low |
| Jan 30, 2026 | Goldan Keith A. Executive | Other | Common Stock | $10.3K | +1K +1.32% | 93,671 0.10% of shares | low |
| Feb 4, 2026 | Rizo Aleksandra Director | Grant | Common Stock | $0 | +24K +96.00% | 49,000 0.05% of shares | low |
| Feb 4, 2026 | Jarrett Jennifer Director | Grant | Common Stock | $0 | +24K +26.67% | 114,000 0.13% of shares | low |
| Feb 4, 2026 | Huber Martin H. Jr. Director | Grant | Common Stock | $0 | +24K +30.38% | 103,000 0.12% of shares | low |
| Feb 4, 2026 | Metzger Michael A CEO | Grant | Common Stock | $0 | +145K +38.91% | 516,261 0.58% of shares | low |
| Feb 4, 2026 | Metzger Michael A CEO | Grant | Common Stock | $0 | +73K +24.44% | 371,661 0.42% of shares | low |
| Feb 4, 2026 | Goldan Keith A. Executive | Grant | Common Stock | $0 | +31K +26.70% | 145,921 0.16% of shares | low |
| Feb 4, 2026 | Goldan Keith A. Executive | Grant | Common Stock | $0 | +22K +22.95% | 115,171 0.13% of shares | low |
| Feb 4, 2026 | Botwood Nicholas A.J. Executive | Grant | Common Stock | $0 | +36K +60.85% | 95,165 0.11% of shares | low |
| Feb 4, 2026 | Botwood Nicholas A.J. Executive | Grant | Common Stock | $0 | +24K +68.25% | 59,165 0.07% of shares | low |
| Feb 4, 2026 | Podlesak Dennis Director | Grant | Common Stock | $0 | +48K +25.03% | 239,763 0.27% of shares | low |
| Feb 4, 2026 | Katkin Keith Director | Grant | Common Stock | $0 | +24K +24.00% | 124,000 0.14% of shares | low |
| Feb 4, 2026 | Legault Pierre Director | Grant | Common Stock | $0 | +24K +26.67% | 114,000 0.13% of shares | low |
| Jun 12, 2026 | Botwood Nicholas A.J. Executive | Exercise | Stock options (Right to buy) | — | +31K | 0 0.00% of shares | low |
| Jun 11, 2026 | Botwood Nicholas A.J. Executive | Exercise | Stock options (Right to buy) | — | +23K | 0 0.00% of shares | low |
| Feb 4, 2026 | Metzger Michael A CEO | Grant | Stock Options (Right to buy) | — | +440K | 440,000 0.49% of shares | low |
| Feb 4, 2026 | Goldan Keith A. Executive | Grant | Stock Options (Right to buy) | — | +118K | 118,000 0.13% of shares | low |
| Feb 4, 2026 | Botwood Nicholas A.J. Executive | Grant | Stock Options (Right to buy) | — | +145K | 144,700 0.16% of shares | low |